Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome

NCT02333760 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Wiskott-Aldrich Syndrome

Interventions

GENETIC: Autologous CD34+ cells transduced with WASP lentiviral vector

Sponsor

Genethon